Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
  • Submit
  • About
    • Editorial Board
    • PNAS Staff
    • FAQ
    • Accessibility Statement
    • Rights and Permissions
    • Site Map
  • Contact
  • Journal Club
  • Subscribe
    • Subscription Rates
    • Subscriptions FAQ
    • Open Access
    • Recommend PNAS to Your Librarian

User menu

  • Log in
  • My Cart

Search

  • Advanced search
Home
Home
  • Log in
  • My Cart

Advanced Search

  • Home
  • Articles
    • Current
    • Special Feature Articles - Most Recent
    • Special Features
    • Colloquia
    • Collected Articles
    • PNAS Classics
    • List of Issues
  • Front Matter
    • Front Matter Portal
    • Journal Club
  • News
    • For the Press
    • This Week In PNAS
    • PNAS in the News
  • Podcasts
  • Authors
    • Information for Authors
    • Editorial and Journal Policies
    • Submission Procedures
    • Fees and Licenses
  • Submit
Research Article

NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition

View ORCID ProfileAlexandra M. Moore, View ORCID ProfileLei Zhou, View ORCID ProfileJing Cui, Luyi Li, Nanping Wu, Alice Yu, Soumya Poddar, View ORCID ProfileKeke Liang, Evan R. Abt, View ORCID ProfileStephanie Kim, Razmik Ghukasyan, View ORCID ProfileNooneh Khachatourian, Kristina Pagano, Irmina Elliott, Amanda M. Dann, View ORCID ProfileRana Riahi, Thuc Le, View ORCID ProfileDavid W. Dawson, View ORCID ProfileCaius G. Radu, and Timothy R. Donahue
  1. aDepartment of Surgery, University of California, Los Angeles, CA 90095;
  2. bDavid Geffen School of Medicine, University of California, Los Angeles, CA 90095;
  3. cDepartment of Pancreatic and Thyroidal Surgery, Shengjing Hospital, China Medical University, Shenyang 110004, China;
  4. dDepartment of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei 430022, China;
  5. eDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095;
  6. fAhmanson Translational Imaging Division, University of California, Los Angeles, CA 90095;
  7. gDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095;
  8. hJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095

See allHide authors and affiliations

PNAS February 23, 2021 118 (8) e2012469118; https://doi.org/10.1073/pnas.2012469118
Alexandra M. Moore
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
bDavid Geffen School of Medicine, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexandra M. Moore
Lei Zhou
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
cDepartment of Pancreatic and Thyroidal Surgery, Shengjing Hospital, China Medical University, Shenyang 110004, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lei Zhou
Jing Cui
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
dDepartment of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei 430022, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jing Cui
Luyi Li
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nanping Wu
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alice Yu
bDavid Geffen School of Medicine, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soumya Poddar
eDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095;
fAhmanson Translational Imaging Division, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keke Liang
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
cDepartment of Pancreatic and Thyroidal Surgery, Shengjing Hospital, China Medical University, Shenyang 110004, China;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Keke Liang
Evan R. Abt
eDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095;
fAhmanson Translational Imaging Division, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephanie Kim
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
bDavid Geffen School of Medicine, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Stephanie Kim
Razmik Ghukasyan
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
bDavid Geffen School of Medicine, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nooneh Khachatourian
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nooneh Khachatourian
Kristina Pagano
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irmina Elliott
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
bDavid Geffen School of Medicine, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Amanda M. Dann
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
bDavid Geffen School of Medicine, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rana Riahi
gDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rana Riahi
Thuc Le
eDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095;
fAhmanson Translational Imaging Division, University of California, Los Angeles, CA 90095;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David W. Dawson
bDavid Geffen School of Medicine, University of California, Los Angeles, CA 90095;
gDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095;
hJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for David W. Dawson
Caius G. Radu
bDavid Geffen School of Medicine, University of California, Los Angeles, CA 90095;
eDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095;
fAhmanson Translational Imaging Division, University of California, Los Angeles, CA 90095;
hJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Caius G. Radu
  • For correspondence: cradu@mednet.ucla.edu tdonahue@mednet.ucla.edu
Timothy R. Donahue
aDepartment of Surgery, University of California, Los Angeles, CA 90095;
bDavid Geffen School of Medicine, University of California, Los Angeles, CA 90095;
eDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095;
fAhmanson Translational Imaging Division, University of California, Los Angeles, CA 90095;
hJonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90095
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: cradu@mednet.ucla.edu tdonahue@mednet.ucla.edu
  1. Edited by David A. Tuveson, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, and accepted by Editorial Board Member Anton Berns January 14, 2021 (received for review June 19, 2020)

  • Article
  • Figures & SI
  • Info & Metrics
  • PDF
Loading

Significance

A hallmark of pancreatic ductal adenocarcinoma (PDAC) is its extensively reprogrammed metabolic network, in which NAD and its reduced form NADH are critical cofactors. Here, we show that IFN signaling, present in a subset of PDAC tumors, increases consumption of NAD(H) through upregulation of PARP9, PARP10, and PARP14. This NAD(H) consumption results in increased dependence upon NAMPT for the recycling of NAM to salvage NAD pools, thus sensitizing these tumor cells to treatment with pharmacologic NAMPT inhibition by decreasing PDAC cell proliferation and invasion in vitro and suppressing orthotopic tumor growth and liver metastases in vivo through this mechanism.

Abstract

Emerging evidence suggests that intratumoral interferon (IFN) signaling can trigger targetable vulnerabilities. A hallmark of pancreatic ductal adenocarcinoma (PDAC) is its extensively reprogrammed metabolic network, in which nicotinamide adenine dinucleotide (NAD) and its reduced form, NADH, are critical cofactors. Here, we show that IFN signaling, present in a subset of PDAC tumors, substantially lowers NAD(H) levels through up-regulating the expression of NAD-consuming enzymes PARP9, PARP10, and PARP14. Their individual contributions to this mechanism in PDAC have not been previously delineated. Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the NAD salvage pathway, a dominant source of NAD in cancer cells. We found that IFN-induced NAD consumption increased dependence upon NAMPT for its role in recycling NAM to salvage NAD pools, thus sensitizing PDAC cells to pharmacologic NAMPT inhibition. Their combination decreased PDAC cell proliferation and invasion in vitro and suppressed orthotopic tumor growth and liver metastases in vivo.

  • pancreatic cancer
  • interferon
  • NAD
  • NAMPT
  • PARP

Footnotes

  • ↵1A.M.M. and L.Z. contributed equally to this work.

  • ↵2To whom correspondence may be addressed. Email: cradu{at}mednet.ucla.edu or tdonahue{at}mednet.ucla.edu.
  • Author contributions: A.M.M., L.Z., J.C., L.L., N.W., E.R.A., R.G., I.E., A.M.D., C.G.R., and T.R.D. designed research; A.M.M., L.Z., J.C., L.L., N.W., A.Y., S.P., K.L., E.R.A., S.K., R.G., N.K., K.P., I.E., A.M.D., R.R., T.L., D.W.D., and T.R.D. performed research; E.R.A., R.R., T.L., and D.W.D. contributed new reagents/analytic tools; A.M.M., L.Z., J.C., L.L., N.W., S.P., K.L., E.R.A., S.K., R.G., R.R., T.L., C.G.R., and T.R.D. analyzed data; and A.M.M., L.Z., C.G.R., and T.R.D. wrote the paper.

  • Competing interest statement: C.G.R. is a cofounder of Sofie Biosciences and Trethera Corporation. He and the University of California (UC) hold equity in Sofie Biosciences and Trethera Corporation. The intellectual property developed by C.G.R. and licensed by UC to Sofie Biosciences and Trethera Corporation was not used in this study.

  • This article is a PNAS Direct Submission. D.A.T. is a guest editor invited by the Editorial Board.

  • This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.2012469118/-/DCSupplemental.

Data Availability

All study data are included in the article and/or supporting information.

Published under the PNAS license.

View Full Text

References

  1. ↵
    1. R. L. Siegel,
    2. K. D. Miller,
    3. A. Jemal
    , Cancer statistics, 2019. CA Cancer J. Clin. 69, 7–34 (2019).
    OpenUrlCrossRefPubMed
  2. ↵
    1. A. Daemen et al
    ., Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors. Proc. Natl. Acad. Sci. U.S.A. 112, E4410–E4417 (2015).
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. R. Blum,
    2. Y. Kloog
    , Metabolism addiction in pancreatic cancer. Cell Death Dis. 5, e1065 (2014).
    OpenUrlCrossRefPubMed
  4. ↵
    1. C. M. Sousa,
    2. A. C. Kimmelman
    , The complex landscape of pancreatic cancer metabolism. Carcinogenesis 35, 1441–1450 (2014).
    OpenUrlCrossRefPubMed
  5. ↵
    1. C. J. Halbrook,
    2. C. A. Lyssiotis
    , Employing metabolism to improve the diagnosis and treatment of pancreatic cancer. Cancer Cell 31, 5–19 (2017).
    OpenUrlCrossRefPubMed
  6. ↵
    1. H. Ying et al
    ., Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656–670 (2012).
    OpenUrlCrossRefPubMed
  7. ↵
    1. F. R. Auciello et al
    ., A stromal lysolipid-autotaxin signaling axis promotes pancreatic tumor progression. Cancer Discov. 9, 617–627 (2019).
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. J. Son et al
    ., Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature 496, 101–105 (2013).
    OpenUrlCrossRefPubMed
  9. ↵
    1. D. E. Biancur et al
    ., Compensatory metabolic networks in pancreatic cancers upon perturbation of glutamine metabolism. Nat. Commun. 8, 15965 (2017).
    OpenUrlCrossRefPubMed
  10. ↵
    1. C. M. Sousa et al
    ., Pancreatic stellate cells support tumour metabolism through autophagic alanine secretion. Nature 536, 479–483 (2016).
    OpenUrlCrossRefPubMed
  11. ↵
    1. A. Viale et al
    ., Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature 514, 628–632 (2014).
    OpenUrlCrossRefPubMed
  12. ↵
    1. A. Chiarugi,
    2. C. Dölle,
    3. R. Felici,
    4. M. Ziegler
    , The NAD metabolome–A key determinant of cancer cell biology. Nat. Rev. Cancer 12, 741–752 (2012).
    OpenUrlCrossRefPubMed
  13. ↵
    1. L. Liu et al
    ., Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metab. 27, 1067–1080.e5 (2018).
    OpenUrlCrossRefPubMed
  14. ↵
    1. E. Verdin
    , NAD+ in aging, metabolism, and neurodegeneration. Science 350, 1208–1213 (2015).
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. N. R. Fons et al
    ., PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma. Nat. Commun. 10, 3790 (2019).
    OpenUrlCrossRefPubMed
  16. ↵
    1. M. Touat et al
    ., DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. J. Clin. Invest. 128, 1671–1687 (2018).
    OpenUrl
  17. ↵
    1. G. Zhao et al
    ., Discovery of a highly selective NAMPT inhibitor that demonstrates robust efficacy and improved retinal toxicity with nicotinic acid coadministration. Mol. Cancer Ther. 16, 2677–2688 (2017).
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. C. C. Chini et al
    ., Targeting of NAD metabolism in pancreatic cancer cells: Potential novel therapy for pancreatic tumors. Clin. Cancer Res. 20, 120–130 (2014).
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. K. Holen,
    2. L. B. Saltz,
    3. E. Hollywood,
    4. K. Burk,
    5. A. R. Hanauske
    , The pharmacokinetics, toxicities, and biologic effects of FK866, a nicotinamide adenine dinucleotide biosynthesis inhibitor. Invest. New Drugs 26, 45–51 (2008).
    OpenUrlCrossRefPubMed
  20. ↵
    1. A. von Heideman,
    2. A. Berglund,
    3. R. Larsson,
    4. P. Nygren
    , Safety and efficacy of NAD depleting cancer drugs: Results of a phase I clinical trial of CHS 828 and overview of published data. Cancer Chemother. Pharmacol. 65, 1165–1172 (2010).
    OpenUrlCrossRefPubMed
  21. ↵
    1. A. Ravaud et al
    ., Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: An ECSG/EORTC study. Eur. J. Cancer 41, 702–707 (2005).
    OpenUrlCrossRefPubMed
  22. ↵
    1. M. Barraud et al
    ., A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. Oncotarget 7, 53783–53796 (2016).
    OpenUrl
  23. ↵
    1. F. Piacente et al
    ., Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors, and DNA repair. Cancer Res. 77, 3857–3869 (2017).
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. A. Grozio et al
    ., CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells. J. Biol. Chem. 288, 25938–25949 (2013).
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. A. R. Fehr et al
    ., The impact of PARPs and ADP-ribosylation on inflammation and host-pathogen interactions. Genes Dev. 34, 341–359 (2020).
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Q. Zhou et al
    ., Transforming growth factor-β in pancreatic diseases: Mechanisms and therapeutic potential. Pharmacol. Res. 142, 58–69 (2019).
    OpenUrl
  27. ↵
    1. S. Tsai et al
    ., A serum-induced transcriptome and serum cytokine signature obtained at diagnosis correlates with the development of early pancreatic ductal adenocarcinoma metastasis. Cancer Epidemiol. Biomarkers Prev. 28, 680–689 (2019).
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. S. Farajzadeh Valilou,
    2. M. Keshavarz-Fathi,
    3. N. Silvestris,
    4. A. Argentiero,
    5. N. Rezaei
    , The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer. Cytokine Growth Factor Rev. 39, 46–61 (2018).
    OpenUrlCrossRef
  29. ↵
    1. R. B. Batchu et al
    ., Inhibition of interleukin-10 in the tumor microenvironment can restore mesothelin chimeric antigen receptor T cell activity in pancreatic cancer in vitro. Surgery 163, 627–632 (2018).
    OpenUrl
  30. ↵
    1. N. Li,
    2. S. I. Grivennikov,
    3. M. Karin
    , The unholy trinity: Inflammation, cytokines, and STAT3 shape the cancer microenvironment. Cancer Cell 19, 429–431 (2011).
    OpenUrlCrossRefPubMed
  31. ↵
    1. W. M. Schneider,
    2. M. D. Chevillotte,
    3. C. M. Rice
    , Interferon-stimulated genes: A complex web of host defenses. Annu. Rev. Immunol. 32, 513–545 (2014).
    OpenUrlCrossRefPubMed
  32. ↵
    1. V. Carafa et al
    ., Sirtuin functions and modulation: From chemistry to the clinic. Clin. Epigenetics 8, 61 (2016).
    OpenUrl
  33. ↵
    1. A. Chalkiadaki,
    2. L. Guarente
    , The multifaceted functions of sirtuins in cancer. Nat. Rev. Cancer 15, 608–624 (2015).
    OpenUrlCrossRefPubMed
  34. ↵
    1. P. Bai
    , Biology of poly(ADP-ribose) polymerases: The factotums of cell maintenance. Mol. Cell 58, 947–958 (2015).
    OpenUrlCrossRefPubMed
  35. ↵
    1. R. van Horssen et al
    ., Intracellular NAD(H) levels control motility and invasion of glioma cells. Cell. Mol. Life Sci. 70, 2175–2190 (2013).
    OpenUrlCrossRefPubMed
  36. ↵
    1. X. Chen,
    2. E. Song
    , Turning foes to friends: Targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18, 99–115 (2019).
    OpenUrlCrossRefPubMed
  37. ↵
    1. D. von Ahrens,
    2. T. D. Bhagat,
    3. D. Nagrath,
    4. A. Maitra,
    5. A. Verma
    , The role of stromal cancer-associated fibroblasts in pancreatic cancer. J. Hematol. Oncol. 10, 76 (2017).
    OpenUrlCrossRefPubMed
  38. ↵
    1. D. Öhlund et al
    ., Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J. Exp. Med. 214, 579–596 (2017).
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. C. Feig et al
    ., The pancreas cancer microenvironment. Clin. Cancer Res. 18, 4266–4276 (2012).
    OpenUrlAbstract/FREE Full Text
  40. ↵
    1. T. Li,
    2. Z. J. Chen
    , The cGAS-cGAMP-STING pathway connects DNA damage to inflammation, senescence, and cancer. J. Exp. Med. 215, 1287–1299 (2018).
    OpenUrlAbstract/FREE Full Text
  41. ↵
    1. E. D. Tang,
    2. C. Y. Wang
    , Single amino acid change in STING leads to constitutive active signaling. PLoS One 10, e0120090 (2015).
    OpenUrl
  42. ↵
    1. S. Hausmann,
    2. B. Kong,
    3. C. Michalski,
    4. M. Erkan,
    5. H. Friess
    , The role of inflammation in pancreatic cancer. Adv. Exp. Med. Biol. 816, 129–151 (2014).
    OpenUrlCrossRefPubMed
  43. ↵
    1. R. Roshani,
    2. F. McCarthy,
    3. T. Hagemann
    , Inflammatory cytokines in human pancreatic cancer. Cancer Lett. 345, 157–163 (2014).
    OpenUrlCrossRefPubMed
  44. ↵
    1. G. Bellone et al
    ., Cytokine expression profile in human pancreatic carcinoma cells and in surgical specimens: Implications for survival. Cancer Immunol. Immunother. 55, 684–698 (2006).
    OpenUrlCrossRefPubMed
  45. ↵
    1. B. S. Parker,
    2. J. Rautela,
    3. P. J. Hertzog
    , Antitumour actions of interferons: Implications for cancer therapy. Nat. Rev. Cancer 16, 131–144 (2016).
    OpenUrlCrossRefPubMed
  46. ↵
    1. S. A. Samarajiwa,
    2. S. Forster,
    3. K. Auchettl,
    4. P. J. Hertzog
    , INTERFEROME: The database of interferon regulated genes. Nucleic Acids Res. 37, D852–D857 (2009).
    OpenUrlCrossRefPubMed
  47. ↵
    1. J. L. Benci et al
    ., Opposing functions of interferon coordinate adaptive and innate immune responses to cancer immune checkpoint blockade. Cell 178, 933–948.e14 (2019).
    OpenUrlPubMed
  48. ↵
    1. J. L. Benci et al
    ., Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).
    OpenUrlCrossRefPubMed
  49. ↵
    1. M. Mandai et al
    ., Dual faces of IFNγ in cancer progression: A role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin. Cancer Res. 22, 2329–2334 (2016).
    OpenUrlAbstract/FREE Full Text
  50. ↵
    1. H. Liu et al
    ., Tumor-derived IFN triggers chronic pathway agonism and sensitivity to ADAR loss. Nat. Med. 25, 95–102 (2019).
    OpenUrlCrossRef
  51. ↵
    1. A. Sistigu et al
    ., Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301–1309 (2014).
    OpenUrlCrossRefPubMed
  52. ↵
    1. K. L. Feijs et al
    ., ARTD10 substrate identification on protein microarrays: Regulation of GSK3β by mono-ADP-ribosylation. Cell Commun. Signal. 11, 5 (2013).
    OpenUrlCrossRefPubMed
  53. ↵
    1. R. C. Aguiar,
    2. K. Takeyama,
    3. C. He,
    4. K. Kreinbrink,
    5. M. A. Shipp
    , B-aggressive lymphoma family proteins have unique domains that modulate transcription and exhibit poly(ADP-ribose) polymerase activity. J. Biol. Chem. 280, 33756–33765 (2005).
    OpenUrlAbstract/FREE Full Text
  54. ↵
    1. H. Iwata et al
    ., PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation. Nat. Commun. 7, 12849 (2016).
    OpenUrlCrossRef
  55. ↵
    1. C. Sheridan
    , Drug developers switch gears to inhibit STING. Nat. Biotechnol. 37, 199–201 (2019).
    OpenUrlCrossRefPubMed
  56. ↵
    1. J. M. Ramanjulu et al
    ., Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature 564, 439–443 (2018).
    OpenUrlPubMed
  57. ↵
    1. S. R. Mitchell et al
    ., Selective targeting of NAMPT by KPT-9274 in acute myeloid leukemia. Blood Adv. 3, 242–255 (2019).
    OpenUrlAbstract/FREE Full Text
  58. ↵
    1. M. G. Bachem et al
    ., Pancreatic carcinoma cells induce fibrosis by stimulating proliferation and matrix synthesis of stellate cells. Gastroenterology 128, 907–921 (2005).
    OpenUrlCrossRefPubMed
  59. ↵
    1. B. E. Kadera et al
    ., MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One 8, e71978 (2013).
    OpenUrlCrossRefPubMed
  60. ↵
    1. N. H. Terry,
    2. R. A. White
    , Flow cytometry after bromodeoxyuridine labeling to measure S and G2+M phase durations plus doubling times in vitro and in vivo. Nat. Protoc. 1, 859–869 (2006).
    OpenUrlCrossRefPubMed
  61. ↵
    1. I. A. Elliott et al
    ., Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Proc. Natl. Acad. Sci. U.S.A. 116, 6842–6847 (2019).
    OpenUrlAbstract/FREE Full Text
  62. ↵
    1. M. Moris et al
    ., Plectin-1 as a biomarker of malignant progression in intraductal papillary mucinous neoplasms: A multicenter study. Pancreas 45, 1353–1358 (2016).
    OpenUrl

Log in using your username and password

Forgot your user name or password?

Log in through your institution

You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.

Subscribers, for more details, please visit our Subscriptions FAQ.

Please click here to log into the PNAS submission website.

PreviousNext
Back to top
Article Alerts
Email Article

Thank you for your interest in spreading the word on PNAS.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition
(Your Name) has sent you a message from PNAS
(Your Name) thought you would like to see the PNAS web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition
Alexandra M. Moore, Lei Zhou, Jing Cui, Luyi Li, Nanping Wu, Alice Yu, Soumya Poddar, Keke Liang, Evan R. Abt, Stephanie Kim, Razmik Ghukasyan, Nooneh Khachatourian, Kristina Pagano, Irmina Elliott, Amanda M. Dann, Rana Riahi, Thuc Le, David W. Dawson, Caius G. Radu, Timothy R. Donahue
Proceedings of the National Academy of Sciences Feb 2021, 118 (8) e2012469118; DOI: 10.1073/pnas.2012469118

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Request Permissions
Share
NAD+ depletion by type I interferon signaling sensitizes pancreatic cancer cells to NAMPT inhibition
Alexandra M. Moore, Lei Zhou, Jing Cui, Luyi Li, Nanping Wu, Alice Yu, Soumya Poddar, Keke Liang, Evan R. Abt, Stephanie Kim, Razmik Ghukasyan, Nooneh Khachatourian, Kristina Pagano, Irmina Elliott, Amanda M. Dann, Rana Riahi, Thuc Le, David W. Dawson, Caius G. Radu, Timothy R. Donahue
Proceedings of the National Academy of Sciences Feb 2021, 118 (8) e2012469118; DOI: 10.1073/pnas.2012469118
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Mendeley logo Mendeley

Article Classifications

  • Biological Sciences
  • Medical Sciences
Proceedings of the National Academy of Sciences: 118 (8)
Table of Contents

Submit

Sign up for Article Alerts

Jump to section

  • Article
    • Abstract
    • Results
    • Discussion
    • Materials and Methods
    • Data Availability
    • Acknowledgments
    • Footnotes
    • References
  • Figures & SI
  • Info & Metrics
  • PDF

You May Also be Interested in

Setting sun over a sun-baked dirt landscape
Core Concept: Popular integrated assessment climate policy models have key caveats
Better explicating the strengths and shortcomings of these models will help refine projections and improve transparency in the years ahead.
Image credit: Witsawat.S.
Model of the Amazon forest
News Feature: A sea in the Amazon
Did the Caribbean sweep into the western Amazon millions of years ago, shaping the region’s rich biodiversity?
Image credit: Tacio Cordeiro Bicudo (University of São Paulo, São Paulo, Brazil), Victor Sacek (University of São Paulo, São Paulo, Brazil), and Lucy Reading-Ikkanda (artist).
Syrian archaeological site
Journal Club: In Mesopotamia, early cities may have faltered before climate-driven collapse
Settlements 4,200 years ago may have suffered from overpopulation before drought and lower temperatures ultimately made them unsustainable.
Image credit: Andrea Ricci.
Click beetle on a leaf
How click beetles jump
Marianne Alleyna, Aimy Wissa, and Ophelia Bolmin explain how the click beetle amplifies power to pull off its signature jump.
Listen
Past PodcastsSubscribe
Birds nestling on tree branches
Parent–offspring conflict in songbird fledging
Some songbird parents might improve their own fitness by manipulating their offspring into leaving the nest early, at the cost of fledgling survival, a study finds.
Image credit: Gil Eckrich (photographer).

Similar Articles

Site Logo
Powered by HighWire
  • Submit Manuscript
  • Twitter
  • Facebook
  • RSS Feeds
  • Email Alerts

Articles

  • Current Issue
  • Special Feature Articles – Most Recent
  • List of Issues

PNAS Portals

  • Anthropology
  • Chemistry
  • Classics
  • Front Matter
  • Physics
  • Sustainability Science
  • Teaching Resources

Information

  • Authors
  • Editorial Board
  • Reviewers
  • Subscribers
  • Librarians
  • Press
  • Site Map
  • PNAS Updates
  • FAQs
  • Accessibility Statement
  • Rights & Permissions
  • About
  • Contact

Feedback    Privacy/Legal

Copyright © 2021 National Academy of Sciences. Online ISSN 1091-6490